Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19357447 | ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF | October 2025 | January 2026 | Allow | 3 | 0 | 0 | No | No |
| 19320604 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | September 2025 | February 2026 | Allow | 5 | 1 | 1 | No | No |
| 19311344 | Selective Serotonin Receptor Modulators and Methods of Making and Using the Same | August 2025 | January 2026 | Allow | 5 | 1 | 1 | Yes | No |
| 19307340 | READY-TO-USE ORAL LIQUID FORMULATION OF CLONIDINE | August 2025 | October 2025 | Allow | 2 | 0 | 0 | No | No |
| 19299605 | PROCESSES OF MAKING CSF-1R INHIBITORS AND METHODS OF USE THEREOF | August 2025 | March 2026 | Allow | 7 | 1 | 1 | No | No |
| 19261393 | COMPOUND, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, SYNTHESIS METHOD THEREFOR AND USE THEREOF | July 2025 | March 2026 | Allow | 8 | 2 | 0 | No | No |
| 19252084 | TOPICAL COMPOSITION | June 2025 | January 2026 | Allow | 7 | 1 | 0 | Yes | No |
| 19222910 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | May 2025 | December 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19221260 | USE OF S-BETA-HYDROXYBUTYRATE COMPOUNDS FOR INDUCTION AND MAINTENANCE OF FLOW | May 2025 | September 2025 | Allow | 4 | 1 | 0 | No | No |
| 19209668 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | May 2025 | December 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 19204307 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | May 2025 | October 2025 | Allow | 5 | 1 | 0 | No | No |
| 19196471 | RAS INHIBITORS | May 2025 | June 2025 | Allow | 1 | 0 | 0 | No | No |
| 19196483 | RAS INHIBITORS | May 2025 | March 2026 | Abandon | 10 | 1 | 0 | No | No |
| 19189002 | WRAPPED INHALABLE SUBSTANCE | April 2025 | June 2025 | Allow | 1 | 0 | 0 | No | No |
| 19177248 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | April 2025 | August 2025 | Allow | 4 | 1 | 0 | No | No |
| 19170770 | ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS | April 2025 | February 2026 | Allow | 10 | 1 | 0 | No | No |
| 19096210 | METHODS FOR TREATING NEUTROPENIA | March 2025 | June 2025 | Allow | 3 | 0 | 0 | No | No |
| 19088147 | BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | March 2025 | December 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 19070930 | RAS INHIBITORS | March 2025 | June 2025 | Allow | 3 | 1 | 0 | No | No |
| 19068133 | RAS INHIBITORS | March 2025 | August 2025 | Allow | 5 | 1 | 0 | No | No |
| 19062331 | RAS INHIBITORS | February 2025 | June 2025 | Allow | 3 | 1 | 0 | No | No |
| 19054330 | NOREPINEPHRINE COMPOSITIONS AND METHODS THEREFOR | February 2025 | August 2025 | Allow | 6 | 1 | 0 | No | No |
| 19053277 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | February 2025 | April 2025 | Allow | 2 | 0 | 0 | No | No |
| 19050993 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | February 2025 | September 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 19043910 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | February 2025 | November 2025 | Allow | 60 | 1 | 1 | Yes | No |
| 19042105 | COMPOSITIONS AND METHODS FOR TREATING NEURODEVELOPMENTAL DISORDERS | January 2025 | April 2025 | Allow | 2 | 0 | 0 | No | No |
| 19038532 | WRN INHIBITORS | January 2025 | March 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19029360 | METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASIS | January 2025 | October 2025 | Allow | 9 | 1 | 1 | No | No |
| 19029592 | METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASIS | January 2025 | November 2025 | Allow | 10 | 1 | 1 | No | No |
| 19009260 | PHARMACEUTICAL DRUG CONTAINING HETEROCYCLIDENE ACETAMIDE DERIVATIVE | January 2025 | August 2025 | Allow | 8 | 2 | 0 | No | No |
| 19001859 | AGENT FOR INHIBITING RENAL DAMAGE INDUCED BY RHABDOMYOLYSIS | December 2024 | October 2025 | Abandon | 10 | 1 | 0 | Yes | No |
| 18970835 | AZACYCLOALKYL CARBONYL CYCLIC AMINE COMPOUND | December 2024 | October 2025 | Allow | 10 | 1 | 1 | Yes | No |
| 18916325 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | October 2024 | October 2025 | Abandon | 12 | 2 | 0 | No | No |
| 18909401 | METHODS FOR TREATING HYPERTROPHIC CARDIOMYOPATHY | October 2024 | June 2025 | Allow | 8 | 2 | 0 | No | No |
| 18905520 | GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERS | October 2024 | April 2025 | Allow | 7 | 1 | 0 | No | No |
| 18905534 | GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERS | October 2024 | April 2025 | Allow | 6 | 1 | 0 | No | No |
| 18905502 | GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERS | October 2024 | February 2025 | Allow | 5 | 1 | 0 | No | No |
| 18895044 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | September 2024 | March 2025 | Allow | 5 | 0 | 0 | No | No |
| 18895095 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | September 2024 | February 2025 | Allow | 5 | 1 | 0 | No | No |
| 18891536 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | September 2024 | October 2025 | Abandon | 13 | 2 | 0 | Yes | No |
| 18892179 | Electronic Inhalation Device | September 2024 | February 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18271036 | HYDROXYPENTYL BENZOIC ACID DIESTER COMPOUND, AND PREPARATION METHOD AND PHARMACEUTICAL APPLICATION THEREOF | September 2024 | June 2025 | Allow | 24 | 0 | 1 | No | No |
| 18814513 | Therapeutic mouthwash containing doxycycline and method of preventing COVID infection using the therapeutic mouthwash | August 2024 | June 2025 | Abandon | 9 | 0 | 1 | No | No |
| 18794778 | STABLE LIQUID COMPOSITIONS OF NETUPITANT AND PALONOSETRON | August 2024 | March 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18790708 | PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERS | July 2024 | March 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18784243 | PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERS | July 2024 | April 2025 | Allow | 8 | 2 | 0 | No | No |
| 18777896 | USE OF ITACONATE AND ITS DERIVATIVES/ANALOGUES TO INDUCE HAIR GROWTH | July 2024 | January 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 18773435 | TOPICAL PEEL-OFF CREAM FOR NUMBING PAIN DURING SKIN-RELATED PROCEDURES | July 2024 | May 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18764024 | FORMULATIONS AND METHODS FOR SKIN CARE OR HYALURONIC ACID SYNTHESIS | July 2024 | January 2025 | Allow | 7 | 1 | 0 | No | No |
| 18760811 | METHODS FOR TREATING MAJOR DEPRESSIVE DISORDER AND TREATMENT-RESISTANT DEPRESSION | July 2024 | January 2026 | Abandon | 19 | 3 | 0 | No | No |
| 18745002 | INHIBITION OF CRYSTAL GROWTH OF ROFLUMILAST | June 2024 | February 2025 | Allow | 8 | 1 | 0 | No | No |
| 18680463 | THERAPEUTIC COMPOSITION, METHODS, AND USES FOR THE CONTROL OF SEIZURES | May 2024 | December 2025 | Abandon | 18 | 2 | 1 | No | No |
| 18670632 | EFFECTIVE TREATMENT OF DEPRESSION IN PATIENTS HAVING IMPAIRED LEARNING AND/OR MEMORY OR CERTAIN EEG CHARACTERISTICS WITH A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | May 2024 | March 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18668552 | 4,5-BIS(4-BROMOPHENYL)-2-(4-BROMOPHENYL)-1-HEXYL-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUND | May 2024 | July 2024 | Allow | 2 | 0 | 0 | No | No |
| 18664847 | FORMULATIONS FOR THE TREATMENT OF OCULAR SURFACE DISEASES AND RELATED METHODS | May 2024 | January 2026 | Abandon | 20 | 1 | 1 | No | No |
| 18662706 | 1-[4,5-BIS(4-CHLOROPHENYL)-1-HEXYL-1H-IMIDAZOL-2-YL]-2-NAPHTHOL AS AN ANTIMICROBIAL COMPOUND | May 2024 | July 2024 | Allow | 2 | 0 | 0 | No | No |
| 18661516 | USE OF ADAMANTANE COMPOSITIONS AND METHODS OF REDUCING FIBROTIC TISSUE | May 2024 | April 2025 | Allow | 11 | 1 | 1 | No | No |
| 18653662 | TOPICAL ROFLUMILAST FORMULATION HAVING IMPROVED DELIVERY AND PLASMA HALF- LIFE | May 2024 | March 2025 | Allow | 10 | 1 | 0 | No | No |
| 18652721 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND DISORDERS | May 2024 | February 2025 | Allow | 9 | 0 | 1 | No | No |
| 18646306 | ETHYL-2-{[(2,4-DICHLOROBENZOYL)CARBAMOTHIOYL]AMINO}-4,5,6,7- TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXYLATE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | April 2024 | October 2024 | Allow | 6 | 1 | 0 | No | No |
| 18646222 | ETHYL-2-{[(2,4-DICHLOROBENZOYL)CARBAMOTHIOYL]AMINO}-4,5,6,7- TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXYLATE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | April 2024 | September 2024 | Allow | 5 | 0 | 1 | No | No |
| 18643253 | VASOCONSTRICTION COMPOSITIONS AND METHODS OF USE | April 2024 | September 2025 | Allow | 16 | 2 | 1 | No | No |
| 18632351 | FIVE-MEMBERED-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | April 2024 | February 2025 | Allow | 11 | 2 | 1 | Yes | No |
| 18631518 | 6-(4,5-BIS(4-BROMOPHENYL)-2-(4-METHOXYPHENYL)-1H-IMIDAZOL-1-YL)HEXANOIC ACID AS AN ANTIMICROBIAL COMPOUND | April 2024 | October 2024 | Allow | 6 | 1 | 0 | No | No |
| 18629099 | METHODS OF TREATING ACUTE CORONARY SYNDROME USING 3,3'-DIINDOLYLMETHANE | April 2024 | September 2025 | Allow | 18 | 1 | 1 | Yes | No |
| 18628297 | 1-[2-(AMINOMETHYL)BENZYL]-2-THIOXO-1,2,3,5-TETRAHYDRO-4H-PYRROLO[3,2-d]PYRIMIDIN-4-ONES AS INHIBITORS OF MYELOPEROXIDASE | April 2024 | October 2025 | Allow | 19 | 1 | 0 | No | No |
| 18621580 | METHOD OF TREATING EXPRESSIVE LANGUAGE DEFICIT IN AUTISTIC HUMANS | March 2024 | December 2025 | Allow | 20 | 2 | 0 | Yes | No |
| 18621624 | PRESBYOPIA TREATMENTS | March 2024 | October 2025 | Abandon | 19 | 1 | 1 | No | No |
| 18620897 | METHOD OF TREATING EXPRESSIVE LANGUAGE DEFICIT IN AUTISTIC HUMANS | March 2024 | March 2026 | Abandon | 23 | 2 | 0 | No | No |
| 18621023 | PHARMACEUTICAL COMPOSITIONS COMPRISING (2S)-N-{(1S)-1-CYANO-2-[4-(3-METHYL-2-OXO-2,3-DIHYDRO-1,3-BENZOXAZOL-5-yl)PHENYL]ETHYL}-1,4- OXAZEPANE-2-CARBOXAMIDE | March 2024 | September 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18618149 | ORALLY ADMINISTERED COMBINATIONS OF AMOXICILLIN AND AVIBACTAM DERIVATIVES FOR TREATING MYCOBACTERIAL INFECTIONS | March 2024 | February 2026 | Abandon | 23 | 1 | 1 | No | No |
| 18616762 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | March 2024 | October 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18616903 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | March 2024 | October 2024 | Allow | 7 | 1 | 0 | No | No |
| 18616995 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | March 2024 | November 2024 | Allow | 7 | 1 | 0 | No | No |
| 18614442 | PI3K-ALPHA INHIBITOR AND MTOR INHIBITOR COMBINATIONS FOR CANCER TREATMENT | March 2024 | November 2025 | Abandon | 19 | 3 | 1 | No | No |
| 18612545 | 2-AMINO-4-(4-BROMOPHENYL)-6-METHOXYPYRIDINE-3,5-DICARBONITRILE AS AN ANTIBACTERIAL COMPOUND | March 2024 | September 2024 | Allow | 6 | 1 | 0 | No | No |
| 18612563 | 2-AMINO-4-(4-BROMOPHENYL)-6-METHOXYPYRIDINE-3,5-DICARBONITRILE AS AN ANTIBACTERIAL COMPOUND | March 2024 | September 2024 | Allow | 6 | 1 | 0 | No | No |
| 18612665 | CHEMICALLY MODIFIED CURCUMINS FOR USE IN THE PRODUCTION OF LIPOXINS | March 2024 | March 2026 | Abandon | 23 | 2 | 1 | No | No |
| 18610777 | SOLID STATE FORMS OF MAVACAMTEN AND PROCESS FOR PREPARATION THEREOF | March 2024 | January 2025 | Allow | 10 | 3 | 1 | Yes | No |
| 18608816 | Modulators of STING (Stimulator of Interferon Genes) | March 2024 | September 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18603789 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE | March 2024 | July 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18603816 | OXYSTEROLS AND METHODS OF USE THEREOF | March 2024 | December 2024 | Allow | 9 | 1 | 0 | No | No |
| 18602435 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | March 2024 | December 2025 | Allow | 21 | 1 | 1 | No | No |
| 18594172 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | March 2024 | November 2024 | Allow | 8 | 1 | 0 | No | No |
| 18594194 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | March 2024 | March 2025 | Allow | 12 | 1 | 1 | No | No |
| 18592262 | USE OF S-BETA-HYDROXYBUTYRATE COMPOUNDS FOR INDUCTION AND MAINTENANCE OF FLOW | February 2024 | February 2025 | Allow | 12 | 1 | 0 | Yes | No |
| 18687803 | BIFLAVONE COMPOUND AGAINST I-TYPE HERPES SIMPLEX VIRUS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | February 2024 | August 2024 | Allow | 5 | 1 | 0 | No | No |
| 18589688 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | February 2024 | February 2025 | Allow | 11 | 1 | 1 | No | No |
| 18589636 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | February 2024 | November 2024 | Allow | 9 | 1 | 0 | No | No |
| 18590387 | SALTS AND ESTERS OF APX3330 AND THERAPEUTIC USES THEREOF | February 2024 | January 2025 | Allow | 11 | 1 | 2 | No | No |
| 18588730 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | February 2024 | February 2026 | Allow | 24 | 2 | 0 | Yes | Yes |
| 18585872 | 3-(2,4,5-TRIS(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)PROPANOIC ACID AS AN ANTIMICROBIAL COMPOUND | February 2024 | April 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18586021 | PYRROLO[3,2-C][2,6]NAPHTHYRIDINE-2-CARBOXYLIC ACID COMPOUNDS AS CK2 INHIBITORS | February 2024 | October 2024 | Allow | 8 | 1 | 1 | No | No |
| 18586070 | PYRROLO[3,2-C][2,6]NAPHTHYRIDINE-2-CARBOXYLIC ACID COMPOUNDS AS CK2 INHIBITORS | February 2024 | August 2024 | Allow | 6 | 1 | 0 | No | No |
| 18583643 | TETRACYCLINE COMPOSITIONS | February 2024 | August 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18444310 | READY-TO-USE INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING NEOSTIGMINE AND GLYCOPYRROLATE | February 2024 | August 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18442061 | COMPOSITIONS AND METHODS FOR TREATING EPILEPSY | February 2024 | November 2024 | Allow | 9 | 1 | 1 | No | No |
| 18440388 | ARIPIPRAZOLE FORMULATIONS HAVING INCREASED INJECTION SPEEDS | February 2024 | February 2026 | Allow | 24 | 2 | 1 | Yes | No |
| 18439517 | SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FOR TREATMENT OF LEPTIN-RESISTANT OBESITY | February 2024 | May 2025 | Abandon | 15 | 2 | 1 | No | No |
| 18437438 | Oral (17-ß)-3-Oxoandrost-4-EN-17-YL Tridecanoate Therapy | February 2024 | September 2025 | Abandon | 19 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1628.
With a 27.4% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Art Unit 1628 is part of Group 1620 in Technology Center 1600. This art unit has examined 16,474 patent applications in our dataset, with an overall allowance rate of 48.8%. Applications typically reach final disposition in approximately 30 months.
Art Unit 1628's allowance rate of 48.8% places it in the 7% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.
Applications in Art Unit 1628 receive an average of 2.07 office actions before reaching final disposition (in the 65% percentile). The median prosecution time is 30 months (in the 53% percentile).
When prosecuting applications in this art unit, consider the following:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.